相关实验视频

Updated: Jan 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

协同作用的MDM2-STAT3抑制在急性淋巴细胞白血病中显示出强烈的抗白血病疗效

Erhan Aptullahoglu^1,2, Emrah Kaygusuz¹

¹Department of Molecular Biology and Genetics, Faculty of Science, Bilecik Şeyh Edebali University, 11100 Bilecik, Türkiye.

International journal of molecular sciences

|September 13, 2025

概括

结合MDM2和STAT3抑制剂对急性淋巴细胞白血病 (ALL) 的治疗有希望. 这种组合疗法增强了亡并抑制了特定ALL亚型的瘤生长,提供了新的治疗选择.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

急性淋巴细胞白血病 (ALL) 存在重大治疗挑战,特别是在高危人群中.
下一代测序已经确定了影响ALL预后和治疗的关键突变.
现有的疗法如TKI,单克隆抗体和CAR T细胞具有局限性和毒性.

研究的目的:

在人类ALL细胞系中研究结合RG7388 (MDM2抑制剂) 和BBI608 (STAT3抑制剂) 的疗效.
评估TP53和STAT3突变对治疗反应的影响.
探索组合治疗的协同效应和潜在机制.

主要方法:

用RG7388和BBI608作为单个药物和组合治疗ALL细胞系.
使用XTT试验量化细胞活力的量化.
通过流细胞计,免疫阻塞和qRT-PCR进行基因/蛋白质表达分析来评估亡.

主要成果:

RG7388抑制了生长,但p53-突变ALL细胞表现出抵抗力.
BBI608在具有可变灵敏度的细胞系中降低了活力.
组合疗法显示出协同作用的抗增殖效应,并在p53野生型和部分功能p53-突变ALL细胞中增强了亡.
具有并发TP53和STAT3突变的MOLT-4细胞对这种组合表现出耐药性.

结论:

结合MDM2和STAT3抑制是针对特定ALL亚群的潜在治疗策略,特别是那些具有野生型或部分功能p53的亚群.
这种方法增强了亡和瘤抑制,扩大了治疗选择.
需要进一步的研究来验证这些发现,并探索在各种ALL种群中的翻译应用.

关键词:

BBI608 (纳巴布卡辛) 的使用这就是MDM2DM2的意思.RG7388 (伊达萨努特林) 的使用情况在STAT3中,我们可以使用STAT3.急性淋巴细胞白血病 (ALL)有针对性的癌症疗法.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...